Zacks Investment Research on MSN
Can Alnylam's pipeline drugs sustain long-term growth ahead?
Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo and Amvuttra — that together generated $2.99 billion in net product revenues, representing a 81% ...
Small-cap stocks advanced in Q4, despite increased volatility that appeared primarily driven by government shutdown and ...
PGIM Jennison Health Sciences Fund outperformed its index in Q4 2025, led by Eli Lilly and Arcutis. Read the full analysis for more details.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results